OSNAT 800 IO for Diabetic Retinopathy
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new eye imaging technology for people with diabetic retinopathy, a condition that can lead to vision loss. The goal is to determine if the OSNAT 800 IO device can successfully track eye movements in real-time while capturing 3D images of the eye. People diagnosed with diabetic retinopathy who have clear vision in both eyes might be suitable candidates for this study. It offers a chance to contribute to the development of better methods for monitoring and managing eye health. As an unphased trial, this study provides an opportunity to contribute to innovative research that could enhance eye care for many.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that the OSNAT 800 IO device is safe for retinal imaging?
Research has shown that the OSNAT 800 IO device is being tested to capture 3D images of the eye and track eye movements in real time for individuals with diabetic retinopathy, a condition that can lead to vision loss. This study focuses on verifying the device's functionality rather than its safety in the traditional sense.
Specific safety data for the OSNAT 800 IO device from previous studies is not available. However, similar devices generally pose a low risk because they are non-invasive, meaning they do not involve surgery or entering the body. Most individuals experience little to no discomfort during eye imaging.
Since the trial does not involve testing a new drug or surgery, and based on the performance of similar devices, it is reasonable to consider the OSNAT 800 IO likely safe and well-tolerated. Participants will have their eyes imaged with the device during a regular care appointment, indicating that any risk is minimal.12345Why are researchers excited about this trial?
Researchers are excited about the OSNAT 800 IO because it offers a real-time eye tracking and imaging solution for diabetic retinopathy patients, which could provide more immediate and precise monitoring compared to standard imaging methods like fundus photography or optical coherence tomography. Unlike existing treatments that focus on managing symptoms or slowing disease progression, this device enhances diagnostic capabilities by capturing detailed images during routine eye exams. This advancement could lead to earlier detection of changes in the eye, allowing for timely interventions and potentially better outcomes for patients.
What evidence suggests that the OSNAT 800 IO is effective for real-time eye tracking in diabetic retinopathy?
Research shows that the OSNAT 800 IO, used by participants in this trial, is a promising tool for diabetic retinopathy. This device captures 3D images of the eye and tracks eye movements in real-time. Early results suggest it excels at capturing detailed images of the retina. It may help identify early changes in the eyes of people with diabetes, potentially improving monitoring and treatment planning. However, further studies are needed to confirm its effectiveness in reducing vision loss.12467
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Retinal Imaging
Participants undergo retinal imaging using the OSNAT800 IO device to assess real-time eye tracking capabilities
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- OSNAT 800 IO
Find a Clinic Near You
Who Is Running the Clinical Trial?
PulseMedica
Lead Sponsor